Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune-Boosting drug may help women with repeated IVF failure

NCT ID NCT07675980

Disease control Sponsor: Fakih IVF Fertility Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests whether Thymosin-α1, an immune-modulating drug, can increase the chance of live birth in women aged 18-40 who have had at least two failed embryo transfers with genetically normal embryos. Participants receive either the drug or a placebo during their IVF cycle and continue until about 11 weeks of pregnancy. The study aims to see if calming the immune system helps the embryo implant and grow.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Thymosin-α1
What this could lead to
If it works, this could offer a new treatment option for women who have repeatedly failed to achieve pregnancy despite using genetically normal embryos.
What could go wrong
This is a mid-stage trial with 136 participants, so results may not apply to all women. The drug may not improve live birth rates and could have side effects like injection site reactions or immune effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. -Women 18-40 years 2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos 3. \- Normal parental karyotypes 4. \- Normal uterine cavity on imaging 5. \- Negative antiphospholipid panel 6. \- Thyroid and prolactin controlled within local reference standards Exclusion Criteria: 1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine) 2. \- Active malignancy 3. -Active infection 4. \- Uncontrolled systemic disease 5. \- Current systemic immunosuppression

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent implantation faliure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent implantation faliure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fakih IVF

    RECRUITING

    Abu Dhabi, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.